ArticleInternational journal of nephrology2026
HLA Profiles of Patients With Chronic Kidney Disease in Central South Africa.
Article in International journal of nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HLA Profiles of Patients With Chronic Kidney Disease in Central South Africa.International journal of nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The human leucocyte antigen (HLA) complex has been associated with the susceptibility of several hundred human diseases, increasingly so with kidney disease. HLA data are under-represented in South Africa, and thus, their contribution to disease characterisation remains poorly understood. Therefore, there is a need for HLA typing studies among high-risk disease populations in our region. Methods: We recruited a total of 100 participants with biopsy-proven chronic kidney disease (CKD) attending a nephrology clinic in central South Africa. Exploratory analyses of demographic, clinical and serological characteristics were performed. High-resolution HLA typing was conducted using DNA microarray technology. Results: Among 100 participants, a large proportion had early-stage CKD based on glomerular filtration rate (GFR) category (CKD stage 1 and 2: 64%), yet many were classified as being at high or very high risk of disease progression to end-stage kidney disease (ESKD) according to the 'Kidney Disease: Improving Global Outcomes' (KDIGO) criteria. This risk was predominantly driven by severely increased proteinuria (proteinuria category A3: 41.8%) rather than reduced estimated GFR (eGFR). Hypertension was the most common comorbidity/complication, and roughly a fifth of the cohort were HIV positive. The most prevalent autoimmune serology was antinuclear antibody (ANA) positivity, occurring in the context of a high frequency of lupus nephritis (LN) in this cohort. We observed the following recurring set of HLA alleles in this CKD cohort, alongside specific clinical and/or serological features: HLA-A∗23:01; HLA-A∗68:02; HLA-B∗15:10; HLA-B∗44:03; HLA-DRB1∗03:01; HLADQB1∗02:01; HLA-DQB1∗02:02 and/or HLA-DPB1∗04:01. Conclusion: Our findings suggest that specific HLA alleles may be associated with CKD susceptibility and/or the increased risk of disease progression in this regional cohort, warranting further investigation into specific CKD-related immunological and molecular mechanisms to establish causality in larger studies. Furthermore, by increasing our global representation in population-specific reference panels, we can improve our understanding of South Africa's extensive genetic diversity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.